Platelets, also called thrombocytes, are small, membrane bound cellular fragments found in the blood that are essential for haemostasis, the set of processes that prevents excessive blood loss after a blood vessel is damaged. Unlike red blood cells and most white blood cells, platelets are not complete cells containing a nucleus. They are fragments produced from very large cells called megakaryocytes in the bone marrow.
A typical platelet is only about 2 to 3 micrometres across, although its structure is highly specialised for rapid responses to vascular injury. Platelets circulate through the bloodstream in a resting state, continuously encountering the endothelial lining of blood vessels. When the vessel wall is damaged and underlying structures become exposed, platelets become activated, change shape, adhere to the injured region and interact with one another. Their central physiological role is therefore not simply to form a plug, but to detect vascular injury, initiate platelet adhesion and aggregation, release signalling substances, provide a surface for coagulation reactions and contribute to subsequent repair of the vessel wall.
Platelet production, known as thrombopoiesis, occurs primarily in the red bone marrow. Haematopoietic stem cells give rise through several developmental stages to megakaryocytes, which become exceptionally large cells with extensive internal DNA replication without normal cell division. Mature megakaryocytes extend long cytoplasmic processes called proplatelets towards blood vessels within the marrow, and portions of these processes fragment to produce circulating platelets.
The hormone thrombopoietin is the principal regulator of platelet production and is produced mainly by the liver, with additional production by other tissues. Thrombopoietin stimulates megakaryocyte development and platelet production through its receptor on megakaryocytic cells and their precursors. Platelets normally circulate for roughly 7 to 10 days before being removed, principally by macrophages in the spleen and liver. The balance between platelet production and clearance helps maintain an appropriate circulating platelet count. Too few platelets is called thrombocytopenia and can increase bleeding risk, whereas an abnormally high platelet count is called thrombocytosis and can be associated with abnormal clotting or, depending on the cause, bleeding.
Resting platelets have a distinctive flattened, discoid shape that helps them circulate efficiently through blood vessels. Their internal organisation includes granules containing biologically active substances, a cytoskeleton that permits rapid shape change, membrane receptors that recognise extracellular molecules, and an open canalicular system that facilitates secretion and membrane trafficking.
Alpha granules contain proteins involved in haemostasis and tissue repair, including fibrinogen, von Willebrand factor and various growth factors, while dense granules contain substances such as adenosine diphosphate, calcium ions and serotonin that participate in platelet activation and recruitment. Platelet membranes contain receptors that bind molecules exposed or generated during vascular injury. The platelet cytoskeleton can reorganise rapidly, causing a resting discoid platelet to extend pseudopodia and become more adhesive. This transformation greatly increases its effective surface area and facilitates interactions with the damaged vessel wall and neighbouring platelets. Consequently, platelets are biologically active fragments rather than inert pieces of cells, and their structure is closely matched to their role in rapid vascular defence.
When a blood vessel is injured, platelets participate in primary haemostasis. Damage to the endothelial lining exposes extracellular matrix components, particularly collagen, and allows circulating plasma proteins such as von Willebrand factor to participate in platelet adhesion. Platelet receptors interact with von Willebrand factor and exposed collagen, allowing platelets to attach to the damaged area, particularly under the high shear conditions found in smaller arteries.
Adhesion triggers platelet activation, during which the cells change shape and release substances from their granules. Released adenosine diphosphate and other mediators recruit and activate additional platelets. Activated platelets also express or activate receptors that allow fibrinogen to link adjacent platelets, producing platelet aggregation. This creates the initial platelet plug. Primary haemostasis is closely connected with secondary haemostasis, in which a series of plasma coagulation reactions produces thrombin and ultimately fibrin. Fibrin strands reinforce the platelet plug, creating a stronger haemostatic clot capable of resisting the forces generated by blood flow.
Platelets have functions beyond the immediate formation of a haemostatic plug. Once activated, they provide a phospholipid rich surface on which several coagulation reactions can occur efficiently. Their membranes help bring coagulation proteins into appropriate proximity, accelerating the generation of thrombin and formation of fibrin. Platelets also interact with endothelial cells, leukocytes and components of the immune system, contributing to inflammation and communication between vascular and immune processes.
Substances released from platelet granules can influence vascular permeability, cell migration, smooth muscle behaviour and tissue repair. Platelets can therefore contribute to wound healing and restoration of damaged vascular tissue. Their role is particularly important because a damaged blood vessel represents both a physical breach and a potential entry point for inflammatory or infectious processes. Platelet responses are consequently integrated with coagulation, inflammation and tissue regeneration rather than operating as an isolated mechanism. Excessive platelet activation, however, can become harmful because a clot forming inside an intact or insufficiently damaged vessel can obstruct blood flow.
Platelet activity is controlled by a balance between activating and inhibitory signals. Healthy vascular endothelium normally discourages unnecessary platelet activation through substances including nitric oxide and prostacyclin, while also presenting a smooth physical barrier between circulating platelets and thrombogenic structures beneath the endothelial layer. After injury, this protective state changes because extracellular matrix proteins become accessible and local chemical signals promote activation. Platelet activation must remain sufficiently localised to prevent uncontrolled clotting throughout the circulation.
Coagulation inhibitors and natural anticoagulant mechanisms contribute to this control, while the fibrinolytic system later breaks down the fibrin network. Plasmin is the principal enzyme responsible for degrading fibrin during fibrinolysis. Platelet contraction also contributes to clot retraction, bringing the edges of a wound closer together and helping organise the clot. These mechanisms illustrate why haemostasis is not equivalent to simple clot formation. Effective haemostasis requires initiation, amplification, localisation, stabilisation and eventual removal or remodelling of the haemostatic structure.
Platelet disorders can affect either the quantity of platelets or their ability to function normally. Thrombocytopenia may result from reduced production in the bone marrow, increased destruction, increased consumption during severe systemic processes, sequestration in an enlarged spleen or combinations of these mechanisms. Clinical manifestations can include easy bruising, prolonged bleeding, petechiae and mucosal bleeding, although the severity depends on the platelet count and underlying cause. Platelet function disorders can produce abnormal bleeding even when the platelet count is normal.
Conversely, excessive platelet activation contributes to arterial thrombosis, in which platelet rich clots can obstruct blood flow and contribute to conditions such as myocardial infarction and ischaemic stroke. Antiplatelet medicines therefore target platelet activation or aggregation and are widely used in cardiovascular medicine. Aspirin, for example, irreversibly inhibits platelet cyclooxygenase activity and reduces production of thromboxane A2, an important platelet activating mediator. Other antiplatelet drugs target specific receptors or signalling pathways. Their therapeutic benefit must always be balanced against increased bleeding risk.
Platelets are therefore best understood as specialised circulating fragments that connect vascular injury detection, primary haemostasis, coagulation, inflammation and tissue repair. They are produced from megakaryocytes rather than developing as conventional independent cells, circulate in large numbers, remain relatively inactive under normal conditions and can transform within seconds when exposed to appropriate injury signals. Their ability to adhere, activate, secrete granule contents, aggregate and support coagulation allows a small vascular injury to be rapidly sealed.
Platelet biology also illustrates an important distinction between normal haemostasis and pathological thrombosis. The same molecular mechanisms that prevent dangerous blood loss can contribute to disease when activation occurs excessively or inappropriately. Platelet count, platelet function, vascular condition, coagulation factors and fibrinolytic activity therefore operate as an interconnected haemostatic system. Understanding platelets is important in physiology, pathology, surgery, emergency medicine, cardiovascular medicine and pharmacology because abnormalities can produce either inadequate clotting and bleeding or excessive clotting and vascular obstruction.
